Silver Book Fact

Potential value of pneumonia vaccine

Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4 billion.

Weycker, Derek, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood, et al. Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years. Vaccine. 2012; 30(36): 5437-44. http://www.sciencedirect.com/science/article/pii/S0264410X12008286

Reference

Title
Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years
Publication
Vaccine
Publication Date
2012
Authors
Weycker, Derek, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood, et al.
Volume & Issue
Volume 30, Issue 36
Pages
5437-44
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Pertussis vaccination reduced global cases
    Vaccination helped reduce global pertussis (whooping cough) cases from 3 million per year to less 250,000.  
  • Value of polio eradication
    Eradication of polio is estimated to produce savings to governments of $1.5 billion per year.  
  • Value of smallpox eradication
    An estimated $100 million spent in eradicating smallpox from 1967 to 1977 saved the world around $1.35 billion a year.  
  • Diptheria vaccine significantly reduced annual cases
    Vaccination has played a significant role in reducing diphtheria cases from 80,000 in 1975 to less than 10,000 per year.  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…